Signal transduction in neuropathic pain, with special emphasis on the analgesic role of opioids - Part II: Moving basic science towards a new pharmacotherapy

Pain Reviews

Volumn 6, Issue 2, 1999, Pages 99-131

  McCormack, Keith ^a,b  

^a Drug Research Group   (United Kingdom)

^b McCormack Limited   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,3 DIHYDRO 1 METHYL 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (3 METHYLPHENYL)UREA; 4 [[2 [2 [[(2 ADAMANTYLOXY)CARBONYL]AMINO] 3 (1H INDOL 3 YL) 2 METHYLPROPIONAMIDO] 1 PHENYLETHYL]AMINO] 4 OXOBUTYRIC ACID MEGLUMINE; 4 BROMO N (2,3 DIHYDRO 1 METHYL 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL)BENZAMIDE; ANALGESIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BETA HYDROXYMEFENTANYL; BUPRENORPHINE; CAM 1481; CHOLECYSTOKININ; CHOLECYSTOKININ A RECEPTOR; CHOLECYSTOKININ B RECEPTOR; CHOLECYSTOKININ B RECEPTOR ANTAGONIST; CROMAKALIM; DEVAZEPIDE; DYNORPHIN A; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; FENTANYL; GLIQUIDONE; LEVORPHANOL; LORGLUMIDE; METHADONE; MORPHICEPTIN[3 (N METHYLPHENYLALANINE) 4 DEXTRO PROLINAMIDE]; MORPHINE; NALOXONE; OPIATE; OPIATE AGONIST; PD 135158; POTASSIUM CHANNEL BLOCKING AGENT; PROGLUMIDE; UNCLASSIFIED DRUG;

ARTICLE; DRUG DESIGN; DRUG MECHANISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; HUMAN; HYPERALGESIA; HYPOTHESIS; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; INTRATHECAL DRUG ADMINISTRATION; NERVE INJURY; NEUROPATHY; NEUROTRANSMISSION; NONHUMAN; PARESTHESIA; SIGNAL TRANSDUCTION;

EID: 0032820566     PISSN: 09681302     EISSN: None     Source Type: Journal    
DOI: 10.1191/096813099669853099     Document Type: Article

References (326)

1. Mann C. Cholecystokinin antagonists: future analgesics. Douleur Analg 1997; 10: 127-30.
2. Martin-Martinez M, Ballaz S, Latorre M et al. 2-oxopyrrolidines and 6-oxoperhydropyrrolo(1,2-a)pyrazines as templates in the search for nonpeptide cholecystokinin ligands. Chem Pharm Bull (Tokyo) 1998; 46: 782-86.
3. Hradahira T, Inoue O, Kobayashi K, Suzuki K. Synthesis and evaluation of 11C-labeled nonpeptide antagonists for cholecystokinin receptors: (11C)L-365,260 and (11C)L-365,346. Nucl Med Biol 1998; 25: 203-208.
4. Vanderhaegen JJ, Signeau JC, Gepts W. New peptide in the vertebrate CNS reacting with gastrin antibodies. Nature 1975; 257: 604-605.
5. Rehfeld JL. Neuronal cholecystokinin. One or two multiple transmitters. J Neurochem 1985; 44: 1-10.
6. Moran TH, Robinson PH, Goldrich MS, McHugh PR. Two brain cholecystokinin receptors: implications for behavioural actions. Brain Res 1986; 362: 175-79.
7. Baile CW, McLaughlin CL, Della Fera MA. Role of cholecystokinin and opioid peptides in control of food intake. Physiol Rev 1986; 66: 172-234.
8. Kachur JF, Miller RJ, Field M. Control of guinea pig intestinal electrolyte secretion by a δ-opioid receptor. Proc Natl Acad Sci U S A 1980; 77: 2753-56.
9. Kachur JF, Wang SX, Gullikson GW, Gaginella TS. Cholecystokinin-mediated ileal electrolyte transport in the guinea pig. Characterization of receptor subtypes. Gastroenterology 1991; 101: 1428-31.
10. Morley JE, Levine AS, Kneip J, Grace M, Billington CJ. The effects of peripherally administered satiety substances on feeding induced by butorphanol tartrate. Pharmacol Biochem Behav 1983; 19: 577-82.
11. Schnur R, Raigoza VP, Sanchez MR, Kulkosky PJ. Cholecystokinin antagonizes morphine induced hypoactivity and hyperactivity in hamsters. Pharmacol Biochem Behav 1986; 25: 1067-70.
12. Itoh S, Katsuura G. Suppressive effect of cholecystokinin and its related peptides on β-endorphin-induced catalepsy in rats. Eur J Pharmacol 1981; 74: 381-84.
13. Felicio LF, Mann PE, Bridges RS. Intracerebroventricular cholecystokinin infusions block β-induced disruption of maternal behaviour. Pharmacol Biochem Behav 1991; 39: 201-204.
14. Kapas L, Benedek G, Penke B. Cholecystokinin interferes with the thermoregulatory effect of exogenous and endogenous opioids. Neuropeptides 1989; 14: 85-92.
15. Mei L, Han JS. The antagonistic effect of cholecystokinin octapeptide (CCK-8) on opioid effects in cardiovascular activities was mediated by CCK-B receptor. Sci China B 1993; 36: 817-23.
16. Miller KK, Lupica CR. Morphine-induced excitation of pyramidal neurones is inhibited by cholecystokinin in the CA1 region on the rat hippocampal slice. J Pharmacol Exp Ther 1994; 268: 753-61.
17. Johannessen JN, Stuckey JA, Phan TH, Boadle-Biber MC. Blockade of morphine-induced increases in brain tryptophan hydroxylase activity by systemic pretreatment with CCK-8: no reversal by vagotomy. Brain Res 1989; 499: 357-62.
18. Bartolome JV, Lorber BA, Bartolome MB. Brain cholecystokinin and β-endorphin systems may antagonistically interact to regulate tissue DNA synthesis in rat pups. Brain Res 1994; 661: 19-24.
19. Faris PL, Komisaruk BR, Watkins LR, Mayer DJ. Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia. Science 1983; 219: 310-12.
20. Han JS, Ding XZ, Fan SG. Is cholecystokinin octapeptide (CCK-8) a candidate for endogenous anti-opioid substrates? Neuropeptides 1985; 5: 399-402.
21. Itoh S, Katsuura G, Maeda Y. Caerulin and cholecystokinin suppress β-endorphin-induced analgesia in the rat. Eur J Pharmacol 1982; 80: 421-25.
22. Li Y, Han JS. Cholecystokinin octapeptide antagonizes morphine analgesia in periaqueductal gray of the rat. Brain Res 1989; 480: 105-10.
23. Suh HH, Collins KA, Tseng F. Intrathecal cholecystokinin octapeptide attenuates the antinociception and release of immunoreactive Met-enkephalin induced by intraventricular β-endorphin in the rat. Neuropeptides 1992; 21: 131-37.
24. Wang XJ, Wang XH, Han JS. Cholecystokinin octapeptide antagonized opioid analgesia mediated by μ-and κ-but not δ-receptors in the spinal cord of the rat. Brain Res 1990; 523: 5-10.
25. Wiesenfeld-Hallin Z, Duranti R. Intrathecal cholecystokinin interacts with morphine but not with substance P in modulating the nociceptive flexor reflex in the rat. Peptides 1987; 8: 153-58.
26. Wiesenfeld-Hallin Z, Xu XJ. Role of cholecystokinin type B receptor in nociception studies with peptide agonists and antagonists. In: Conn PM ed. Methods in neurosciences, vol. II. New York, Academic Press, 1993: 148-69.
27. Zhang LJ, Han NL, Han JS. Regulation by lithium of the antagonistic effect of cholecystokinin octapeptide on ohmefentanyl-induced antinociception. Neuropharmacology 1994; 23: 123-26.
28. Barbaz BS, Hall NR, Liebman JM. Antagonism of morphine analgesia by CCK-8-S does not extend to all assays nor all opiate analgesics. Peptides 1989; 9: 1295-300.
29. Tseng LF, Collins KA. Cholecystokinin administered intrathecally selectively antagonizes intracerebroventricular β-endorphin-induced tailflick inhibition in the mouse. J Pharmacol Exp Ther 1992; 260: 1086-92.
30. Kellstein DE, Price DD, Mayer DJ. Cholecystokinin and its antagonist lorglumide respectively attenuates and facilitates morphine-induced inhibition of C-fiber evoked discharges of dorsal horn nociceptive neurones. Brain Res 1991; 540: 302-306.
31. Baber NS, Dourish CT, Hill DR. The role of CCK, caerulein, and CCK antagonists in nociception. Pain 1989; 39: 307-28.
32. Suberg SN, Culhane ES, Carstens E, Watkins LR. Behavioral and electrophysiological investigations of opiate/cholecystokinin interactions. Adv Pain Res Ther 1985; 9: 541-53.
33. Suberg SN, Culhane ES, Carstens E, Watkins LR. The potentiation of morphine-induced inhibition of spinal transmission by proglumide, a putative cholecystokinin antagonist. Ann N Y Acad Sci 1985; 448: 660-62.
34. Faris PL, McLaughlin CL, Baile CA, Olney JW, Komisaruk BR. Morphine analgesia potentiated but tolerance not affected by active immunization against cholecystokinin. Science 1984; 266: 1215-17.
35. Itoh S, Katsuura G, Yorhikawa K, Rehfeld JF. Potentiation of β-endorphin effects by cholecystokinin antiserum in rats. Can J Physiol Pharmacol 1985; 63: 81-83.
36. Ding XZ, Fan SG, Zhou JP, Han JS. Reversal of tolerance to morphine but not potentiation of morphine induced analgesia by antiserum against cholecystokinin octapeptide. Neuropharmacology 1986; 25: 1155-60.
37. 1 opioid analgesia in mice. Neuropharmacology 1990; 29: 507-10.
38. Dourish CT, Hawley D, Iversen SD. Enhancement of morphine analgesia and prevention of morphine tolerance in the rat by the cholecystokinin antagonist L-364,718. Eur J Pharmacol 1988; 147: 469-72.
39. Dourish CT, O'Neill MF, Coughlan J, Kitchener SJ, Hawley D, Iversen SD. The selective CCK-B receptor antagonist L-365,260 enhances morphine analgesia and prevents morphine tolerance in the rat. Eur J Pharmacol 1990; 176: 35-44.
40. Hendrie CA, Shepherd JK, Rodgers RJ. Differential effects of the CCK antagonist, MK-329, on analgesia induced by morphine, social conflict (opioid) and defeat experience (non-opioid) in male mice. Neuropharmacology 1989; 28: 1025-32.
41. Katsuura G, Itoh S. Potention of β-endorphin effects by proglumide in rats. Eur J Pharmacol 1985; 107: 363-66.
42. Kellstein DE, Mayer DJ. Chronic administration of cholecystokinin antagonists reverses the enhancement of spinal morphine analgesia induced by acute pretreatment. Brain Res 1990; 516: 263-70.
43. Klein H, Jackson R, McCormick G et al. Enhancement of opiate analgesia by devazepide in a baboon dolorimetry model. In: Dourish CT, Cooper CJ, Iversen SD, Iversen LL, eds. Multiple cholecystokinin receptors in the CNS. Oxford: Oxford University Press, 1992: 529-36.
44. Lavigne GJ, Millington WR, Mueller GP. The CCK-A and CCK-B receptor antagonists, devazepide and L-365,260, enhance morphine antinociception only in non-acclimated rats exposed to a novel environment. Neuropeptides 1992; 21: 119-29.
45. O'Neill MF, Dourish CT, Iversen SD. Morphine-induced analgesia in the rat paw pressure test is blocked by CCK and enhanced by the CCK antagonist MK-329. Neuropharmacology 1989; 28: 243-47.
46. Panerai AE, Rovati LC, Cocco E, Sacerdote P, Mantegazza P. Dissociation of tolerance and dependence to morphine: a possible role for cholecystokinin. Brain Res 1987; 410: 52-60.
47. Poggioli R, Vergoni AV, Sandrini M, Barbafiera L, Marrama D, Bertolini A. Influence of the selective cholecystokinin antagonist L-364,718 on pain threshold and morphine analgesia. Pharmacology 1991; 42; 197-201.
48. Rattray M, Jordan CC, De Belleroche J. The novel CCK antagonist L374,718 abolishes calcineurin-but potentiates morphine-induced antinociception. Eur J Pharmacol 1988; 152: 163-66.
49. Rovati LC, Sacerdote P, Panerai AE. Effects of proglumide on morphine analgesia and tolerance. Ann N Y Acad Sci 1985; 448: 630-32.
50. Suh HH, Tseng LF. Differential effects of sulfated cholecystokinin octapeptide and proglumide injected intrathecally on antinociception induced by β-endorphin and morphine administered intracerebroventricularly in mice. Eur J Pharmacol 1990; 179: 329-38.
51. Takeshige C, Mera H, Hisamitsu T, Tanaka M, Hishida F. Inhibition of the analgesia inhibitory system by D-phenylalanine and proglumide. Brain Res 1991; 26: 385-91.
52. Tang J, Chou J, Iadorola M, Yang HYT, Costa E. Proglumide prevents and curtails acute tolerance to morphine in rats. Neuropharmacology 1984; 23: 715-18.
53. Watkins LR, Kinscheck IB, Mayer DJ. Potentiation of opiate analgesia and apparent reversal of morphine tolerance by proglumide. Science 1984; 224: 395-96.
54. Watkins LR, Kinscheck IB, Kaufman EPS, Miller J, Frenk H, Mayer DJ. Cholecystokinin antagonists selectively potentiate analgesia induced by endogenous opiates. Brain Res 1985; 327: 181-90.
55. Watkins LR, Kinscheck IB, Mayer DJ. Potentiation of morphine analgesia by the cholecystokinin antagonist proglumide. Brain Res 1985; 327: 168-80.
56. Watkins LR, Kinscheck IB, Rosenquist G et al. The enhancement of opiate analgesia and the possible reversal or morphine tolerance by proglumide. Ann N Y Acad Sci 1985; 448: 676-77.
57. B receptor antagonist L-365,260 in rat spinal cord. Eur J Pharmacol 1993; 234: 147-54.
58. Dourish CT, O'Neill MF, Schaffer LW, Siegl PKS, Iversen SD. The cholecystokinin receptor antagonist devazepide enhances morphine-induced analgesia but not morphine-induced respiratory depression in the squirrel monkey. J Pharmacol Exp Ther 1990; 255: 1158-65.
59. Maldonado R, Derrien M, Noble F, Roques BP. Association of a peptidase inhibitor and a CCK-B antagonist strongly potentiates antinociception mediated by endogenous enkephalins. NeuroReport 1993; 7: 947-50.
60. O'Neill MF, Dourish CT, Tye SJ, Iversen SD. Blockade of CCK-B receptors by L-365,260 induces analgesia in the squirrel monkey. Brain Res 1990; 534: 287-90.
61. B antagonist in the rat. Neurosci Lett 1994; 181: 9-12.
62. Wiesenfeld-Hallin Z, Xu XJ, Hughes J, Horwell DC, Hökfelt T. PD 134308, a selective antagonist of cholecystokinin type B receptor, enhances the analgesic effect of morphine and synergistically interacts with intrathecal galanin to depress spinal nociceptive reflexes. Proc Natl Acad Sci U S A 1990; 87: 105-109.
63. Wiesenfeld-Hallin Z, Xu XJ, Hughes J, Horwell DC, Hökfelt T. Studies on the effect of systemic PD134308 (CAM 958) in spinal reflex and pain models with special reference to interaction with morphine and intrathecal galanin. Neuropeptides 1991; 19 (suppl): 79-84.
64. 5]enkephalin antiserum-sensitive enhancement of morphine antinociception. NeuroReport 1994; 5: 2601-605.
65. Xu XJ, Puke MJ, Verge VM, Wiesenfeld-Hallin Z, Hughes J, Hökfelt T. Up-regulation of cholecystokinin in primary sensory neurones is associated with morphine insensitivity in experimental neuropathic pain in the rat. Neurosci Lett 1993; 152: 129-32.
66. Xu XJ, Hao JX, Seiger A, Hughes J, Hökfelt T, Wiesenfeld-Hallin Z. Chronic pain-related behaviors in spinally injured rats; evidence for functional alterations of the endogenous cholecystokinin and opioid systems. Pain 1994; 56: 271-77.
67. Xu XJ, Hökfelt T, Hughes J, Wiesenfeld-Hallin Z. The CCK-B antagonist CI988 enhances the reflex-depressive effect of morphine in axotomized rats. NeuroReport 1994; 5: 718-20.
68. Stanfa LC, Dickenson AH. Cholecystokinin as a factor in the enhanced potency of spinal morphine following carrageenin inflammation. Br J Pharmacol 1993; 108: 967-73.
69. 2-adrenergic and opioid spinal antinociception by cholecystokinin and cholecystokinin antagonists in the rat dorsal horn: an electrophysiological study. Brain Res 1994; 662: 141-47.
70. Stanfa L, Dickenson A, Xu XJ, Wiesenfeld-Hallin Z. Cholecystokinin and morphine analgesia: variations on a theme. Trends Pharmacol Sci 1994; 15: 65-66.
71. McRee RC, Meyer DC. GABA control of LHRH release is dependent on the steroid milieu. Neurosci Lett 1993; 57: 227-30.
72. Idanapaan-Haikkila JJ, Guilbaud G, Kayser V. Prevention of tolerance to the antinociceptive effects of systemic morphine by a selective cholecystokinin-B receptor antagonist in a rat model of peripheral neuropathy. J Pharmacol Exp Ther 1997; 282: 1366-72.
73. Verge VM, Wiesenfeld-Hallin Z, Hökfelt T. Cholecystokinin in mammalian primary sensory neurones and spinal cord: in situ hybridization studies in rat and monkey. Eur J Neurosci 1993; 5: 240-50.
74. Ding XZ, Bayer BM. Increases of CCK mRNA in different brain areas following acute and chronic administration of morphine. Brain Res 1993; 625: 139-44.
75. Faris PL, Beinfeld MC, Scallet AC, Johannessen JN, Olney JW. Increase in hypothalamic cholecystokinin following acute and chronic morphine. Brain Res 1986; 367: 405-407.
76. Pu S, Zhuang H, Lu Z, Wu X, Han J. Cholecystokinin gene expression in rat amygdaloid neurons: normal distribution and effect of morphine tolerance. Brain Res Mol Brain Res 1994; 21: 183-89.
77. Zhou Y, Sun YH, Zhang JW, Han JS. Accelerated expression of cholecystokinin in the brain of rats rendered tolerant to morphine. NeuroReport 1992; 3: 1121-23.
78. Ekström PA, Ekman R, Hakanson R. Ontogeny of neuropeptides in the rat urinary bladder. Regul Pept 1994; 50: 23-28.
79. Hoffman O, Wiesenfeld-Hallin Z. The CCK-B receptor antagonist CI988 reverses tolerance to morphine in rats. NeuroReport 1994; 5: 2565-68.
80. Jacquin MF, Beinfeld MC, Chiaia NL, Zahm DS. Cholecystokinin concentrations and peptide immunoreactivity in the intact and deafferented medullary dorsal horn of the rat. J Comp Neurol 1992; 326: 22-43.
81. Sinatra RS, Ford DH. The effects of acute and chronic morphine treatment on the process of facial nerve regeneration. Brain Res 1979; 175: 315-25.
82. Stengaard-Pedersen K, Larsson LI. Localization and opiate receptor binding of enkephalin, CCK and ACTH/β-endorphin in the rat central nervous system. Peptides 1981; 2 (suppl 1): 3-19.
83. Zabin MA, Innis RB, Warmsley JK, Synder SH, Kuhar MJ. Autoradiographic localization of cholecystokinin receptors in rodent brain. J Neurosci 1983; 3: 877-906.
84. Ghilardi JR, Allen CJ, Vigna SR, McVey DC, Mantyh PW. Trigeminal and dorsal root ganglion neurons express CCK receptor binding sites in the rat, rabbit and monkey: possible site of opiate-CCK analgesic interactions. J Neurosci 1992; 12: 4854-66.
85. Schafer M, Zhou L, Stein C. Cholecystokinin inhibits peripheral opioid analgesia in inflamed tissue. Neuroscience 1998; 82: 603-11.
86. B receptors in human brain: no evidence for receptor heterogeneity. Neurosci Lett 1996; 217: 45-49.
87. Cortës R, Arvidsson U, Schalling M, Ceccatelli S, Hökfelt T. In situ hybridization studies on mRNAs for cholecystokinin, calcitonin gene-related peptide and choline acetyltransferase in the lower brainstem, spinal cord and dorsal root ganglia of rat and guinea pig with special reference to motor neurones. J Chem Neuroanat 1990; 3: 467-85.
88. Carlberg M, Gundlach AL, Mercer LD, Beart PM. Autoradiographic localization of cholecystokinin A and B receptors in rat brain using (1251) D-Tyr25 (Nle 28,31)-CCK 25-33S. Eur J Neurosci 1992; 4: 563-73.
89. Hill DR, Shaw TM, Woodruff GN. Binding sites for 125I-cholecystokinin in primate spinal cord are of the CCK-A subclass. Neurosci Lett 1988; 89: 133-39.
90. Beinfeld MC, Meyer DK, Eskay RL, Jensen RT, Brownstein MJ. The distribution of cholecystokinin immunoreactivity in the central nervous system of the rat as determined by radioimmunoassay. Brain Res 1981; 212: 51-57.
91. Gall C, Lauterborn J, Burks D, Seroogy K. Colocalisation of enkephalin and cholecystokinin in discrete areas of rat brain. Brain Res 1987; 403: 403-408.
92. Lin Y, Carpenter DO. Direct excitatory opiate effects mediated by non-synaptic actions on rat medial vestibular neurons. Eur J Pharmacol 1994; 262: 99-106.
93. Hepler JR, Gilman AG. G proteins. Trends Biochem Sci 1992; 17: 383-87.
94. Berridge MJ. Inositol trisphosphate and calcium signalling. Nature 1993; 361: 315-25.
95. Jagerschmidt A, Guillaume N, Goudreau N, Maigret B, Roques BP. Mutation of Asp100 in the second transmembrane domain of the cholecystokinin B receptor increases antagonist binding and reduces signal transduction. Mol Pharmacol 1995; 48: 783-89.
96. B) receptors to phospholipase C and protein kinase C in AR4-2J tumoral cells. Regul Pept 1994; 52: 31-38.
97. Wu T, Wang HL. The excitatory effect of cholecystokinin on rat neostriatal neurones: ionic and molecular mechanisms. Eur J Pharmacol 1996; 307: 125-32.
98. B receptors in guinea pig synaptoneurosomes. Eur J Pharmacol 1992; 226: 35-41.
99. Detjen K, Yule D, Tseng MJ, Williams JA, Logsdon CD. CCK-B receptors produce similar signals but have opposite growth effects in CHO and Swiss 3T3 cells. Am J Physiol 1997; 273: C1449-57.
100. 2+)i increase but not PKC activation in Jurkat T-cells. NeuroReport 1992; 3: 697-99.
101. B/gastrin receptor transfected into rat1 fibroblasts mediates activation of MAPK, p74raf-1 kinase, and mitogenesis. Cell Growth Differ 1995; 6: 383-93.
102. Willems PH, Smeets RL, Bosch RR, Garner KM, Van Mackelenbergh MG, De Pont JJ. Protein kinase C activation inhibits receptor-evoked inositol trisphosphate formation and induction of cytosolic calcium oscillations by decreasing the affinity-state of the cholecystokinin receptor in pancreatic acinar cells. Cell Calcium 1995; 18: 471-83.
103. Shlik A, Vasar E, Bradwejn J. Cholecystokinin and psychiatric disorders. Role in aetiology and potential of receptor antagonists in therapy. CNS Drugs 1997; 8: 134-52.
104. B-receptor-mediated Ca-signaling in hippocampal astrocytes. J Neurophysiol 1997; 78: 1997-2001.
105. Smith AJ, Freedman SB. CCK-B receptor-mediated stimulation of polyphosphoinositide turnover in GH3 pituitary cells in response to cholecystokinin and pentagastrin. Life Sci 1996; 58: 883-95.
106. Boden P, Woodruff GN. Ionic mechanisms underlying cholecystokinin action in rat brain. Ann N Y Acad Sci 1994; 713: 129-37.
107. Wank SA. Cholecystokinin receptors [Editorial]. Am J Physiol 1995; 269: G628-46.
108. Wang HL. Basic amino acids at the C-terminus of the third intracellular loop are required for the activation of phospholipase C by cholecystokinin-B receptors. J Neurochem 1997; 68: 1728-35.
109. Kaufmann R, Schafberg H, Zieger M, Henklein P, Nowak G. Protein kinase C is involved in cholecystokinin octapeptide-induced proliferative action in rat glioma C6 cells. Neuropeptides 1998; 32: 185-89.
110. Tirassa P, Stenfors C, Lundeberg T, Aloe L. Cholecystokinin-8 regulation of NGF concentrations in adult mouse brain through a mechanism involving CCK(A) and CCK(B) receptors. Br J Pharmacol 1998; 123: 1230-36.
111. Wang J, Ren M, Han J. Mobilization of calcium from intracellular stores as one of the mechanisms underlying the antiopioid effect of cholecystokinin octapeptide. Peptides 1992; 13: 947-51.
112. Boden P, Hall MD, Hughes J. Cholecystokinin receptors. Cell Mol Neurobiol 1995: 15: 545-59.
113. Maletinska L, Pirkova J, Hlavacek J, Slaninova J. Cholecystokinin analogs with suppressed central activities. Peptides 1998; 19: 301-308.
114. 2 with μ and δ opioid antinociception in the rat spinal cord. Neuropeptides 1990; 16: 213-18.
115. B receptors in mediating the inhibitory effect of CCK on opiate analgesia. In: Dourish CT ed. Multiple cholecystokinin receptors in the CNS. New York: Oxford University Press, 1991: 455-79.
116. Martin GR, MacLennan SJ, Maxwell M, Smith RR. A general operational model of pharmacological synergism [Abstract]. British Pharmacological Society Meeting, Dundee, UK, 1996: 310P.
117. Daub H, Wallasch C, Lankenau A, Herrlich A, Ullrich A. Signal characteristics of G protein-transactivated EGF receptor. EMBO J 1997; 16: 7032-14.
118. Feng X, Zhang J, Barak LS, Meyer T, Caron MG, Hannun YA. Visualization of dynamic trafficking of a protein kinase C β II/green fluorescent protein conjugate reveals differences in G protein-coupled receptor activation and desensitisation. J Biol Chem 1998; 273: 10755-62.
119. Frantz K, Babcock D, Van Hartesveldt C. The locomotor effects of a putative dopamine D3 receptor agonist in developing rats. Eur J Pharmacol 1996; 302: 1-6.
120. Wu YL, Pei G, Fan GH. Inhibition of phospholipase C blocks opioid receptor-mediated activation of Gi proteins. NeuroReport 1998; 9: 99-103.
121. Fan GH, Zhou TH, Zhang WB, Pei G. Suppression of phospholipase C blocks Gi-mediated inhibition of adenylyl cyclase activity. Eur J Pharmacol 1998; 341: 317-22.
122. Tateishi K, Funakoshi A, Misumi Y, Matsuoka Y. Jun and MAPKs are activated by cholecystokinin in the pancreatic carcinoma cell line KP-IN. Pancreas 1998; 16: 499-504.
123. Nemoz-Gaillard E, Cordier-Bussat M, Filloux C, et al. Bombesin stimulates cholecystokinin secretion through mitogen-activated protein-kinase-dependent and -independent mechanisms on the enteroendocrine STC-1 cell line. Biochem J 1998; 331: 129-35.
124. Dabrowski A, Groblewski GE, Schafter C, Guan KL, Williams JA. Cholecystokinin and EGF activate a MAPK cascade by different mechanisms in rat pancreatic acinar cells. Am J Physiol 1997; 273: C1472-79.
125. Hocker M, Henihan RJ, Rosewicz S et al. Gastrin and phorbol 12-myristate 13-acetate regulate the human histidine decarboxylase promoter through Raf-dependent activation of extracellular signal-regulated kinase-related signaling pathways in gastric cancer cells. J Biol Chem 1997; 272: 27015-24.
126. Todisco A, Takeuchi Y, Urumov A, Yamada J, Stepan VM, Yamada T. Molecular mechanisms for the growth factor action of gastrin. Am J Physiol 1997; 273: G891-98.
127. Dabrowski A, Detjen KM, Logsdon CD, Williams JA. Stimulation of both CCK-A and CCK-B receptors activates MAPKs in AR42J and receptor-transfected CHO cells. Digestion 1997: 58: 361-67.
128. Seva C, Kowalski Chauvel A, Daulhac L, Barthez C, Vaysse N, Pradayrol L. Wortamannin-sensitive activation of p70S6-kinase and MAP-kinase by the G protein-coupled receptor, G/CCKB. Biochem Biophys Res Commun 1997; 238: 202-206.
129. A receptor mechanism. Neuropharmacol 1994; 33: 719-27.
130. Dabrowski A, VanderKuur JA, Carter Su C, Williams JA. Cholecystokinin stimulates formation of the shc-grb2 complex in rat pancreatic acinar cells through a protein kinase C-dependent mechanism. J Biol Chem 1996; 271: 27125-29.
131. Seva C, Kowalski Chauvel A, Blanchet JS, Vaysse N, Pradayrol L. Gastrin induces tyrosine phosphorylation of She proteins and their association with the Grb2-Sos complex. FEBS Lett 1996; 378: 74-78.
132. Duan RD, Zheng CF, Guan KL, Williams JL. Activation of map kinase kinase (MEK) and Ras by cholecystokinin in rat pancreatic acini. Am J Physiol 1995; 268: G1060-65.
133. Duan RD, Williams JA. Cholecystokinin rapidly activates mitogen-activated protein kinase in rat pancreatic acini. Am J Physiol 1994; 267: G401-408.
134. Taniguchi T, Matsui T, Ito M, et al. Cholecystokinin-B/gastrin receptor signaling pathway involves tyrosine phosphorylations of p125FAK and p42MAP. Oncogene 1994; 9: 861-67.
135. 2+ and protein kinase C-dependent mechanisms involved in gastrin-induced Shc/Grb2 complex formation and P44-mitogen-activated protein kinase activation. Biochem J 1997; 325: 383-89.
136. Gutstein HB, Rubie EA, Mansour A, Akil H, Woodgett JR. Opioid effects on mitogen-activated protein kinase signaling cascades. Anesthesiology 1997; 87: 1118-26.
137. Belcheva MM, Vogel Z, Ignatova E et al. Opioid modulation of extracellular signal-regulated protein kinase activity is ras-dependent and involves Gβγ subunits. J Neurochem 1998; 70: 635-45.
138. Burt AR, Carr IC, Mullaney I, Anderson NG, Milligan G. Agonist activation of p42 and p44 mitogen-activated protein kinases following expression of the mouse 6 opioid receptor in Rat-1 fibroblasts: effects of receptor expression levels and comparisons with G-protein activation. Biochem J 1996; 320: 227-325.
139. Chuang LF, Kilam KF, Chuang RY. Induction and activation of mitogen-activated protein kinases of human lymphocytes as one of the signaling pathways of the immunomodulatory effects of morphine sulfate. J Biol Chem 1997; 272: 26815-17.
140. Li L-Y, Chang K-J. The stimulatory effect of opioids on mitogen-activated protein kinase in Chinese hamster ovary cells transfected to express μ-opioid receptors. Mol Pharmacol 1996; 50: 599-602.
141. Ortiz J, Harris HW, Guitart Z, Terwilliger RZ, Haycock JW, Nestler EJ. Extracellular signal-regulated protein kinases (ERKs) and ERK kinase (MEK) in brain: regional distribution and regulation by chronic morphine. J Neurosci 1995; 16: 1285-97.
142. Guitart X, Thompson MA, Mirante CK, Greenberg ME, Nestler EJ. Regulation of cyclic AMP response element-binding protein (CREB) phosphorylation by acute and chronic morphine in the rat locus coeruleus. J Neurochem 1992; 58: 1168-71.
143. Widnell KL, Self DW, Lane SB et al. Regulation of CREB expression: in vivo evidence for a functional role in morphine action in the nucleus accumbens. J Pharmacol Exp Ther 1996; 276: 306-15.
144. Nibuya M, Nestler EJ, Duman RS. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J Neurosci 1996; 16: 2365-72.
145. Couceyro P, Douglass J. Precipitated morphine withdrawal stimulates multiple activator protein-1 signaling pathways in rat brain. Mol Pharmacol 1995; 47: 29-39.
146. Noël F, Iourgenko V, Pouille Y, Hanoune J. Recent advances in molecular effects of opiates. Med Sci 1994; 10: 1116-26.
147. Fukuda K, Kato S, Morikawa H, Shoda T, Mori K. Functional coupling of the δ-, μ-, and κ-opioid receptors to mitogen-activated protein kinase and arachidonate release in Chinese hamster ovary cells. J Neurochem 1996; 67: 1309-16.
148. Fukuda K, Shoda T, Morikawa H, Kato S, Mori K. Activation of mitogen-activated protein kinase by the nociceptin receptor expressed in Chinese hamster ovary cells. FEBS Lett 1997; 412: 290-94.
149. Berhow MT, Russell DS, Terwilliger RZ et al. Influence of neurotrophic factors on morphine-and cocaine-induced biochemical changes in the mesolimbic dopamine system. Neuroscience 1995; 68: 969-79.
150. Berhow MT, Hiroi N, Nestler EJ. Regulation of ERK (extracellular signal regulated kinase), part of the neurotrophin signal transduction cascade, in the rat mesolimbic dopamine system by chronic exposure to morphine or cocaine. J Neurosci 1996; 16: 4707-15.
151. Lou LG, Zhang Z, Ma L, Pei G. Nociceptin/ orphanin FQ activates mitogen-activated protein kinase in Chinese hamster ovary cells expressing opioid receptor-like receptor. J Neurochem 1998; 70: 1316-22.
152. Polakiewicz RD, Schieferl SM, Dorner LF, Kansra V, Comb MJ. A mitogen-activated protein kinase pathway is required for μ-opioid receptor desensitization. J Biol Chem 1998; 273: 12402-406.
153. Nestler EJ, Hope BT, Widnell KL. Drug addiction: a model for the molecular basis of neural plasticity. Neuron 1993; 11: 995-1006.
154. 2+-induced regulation of ion channel and MAPK functions. Nature 1995; 376: 737-45.
155. Bourne HR, Nicoll R. Molecular machines integrate coincident synaptic signals. Cell 1993; 72 (Suppl): 65-75
156. Faure M, Voyno Yasenetskaya T, Bourne HR. cAMP and By subunits of heterotrimeric G proteins stimulate the mitogen-activated protein kinase pathway in COS-7 cells. J Biol Chem 1994; 269: 7851-54.
157. Koch WJ, Hawes BE, Allen LF, Lefkowitz RJ. Direct evidence that Gi-coupled receptor stimulation of mitogen-activated protein kinase is mediated by Gβγ activation of p21 ras. Proc Natl Acad Sci U S A 1994; 91: 12706-10.
158. Hawes BE, Luttrell LM, van Biesen T, Lefkowitz RJ. Phosphatidylinositol 3-kinase is an early intermediate in the Gβγ-mediated mitogen-activated protein kinase signaling pathway. J Biol Chem 1996; 271: 12133-36.
159. Crespo P, Xu N, Simonds WF, Gutkind JS. Ras-dependent activation of MAPK pathway mediated by G-protein βγ subunits. Nature 1994; 369: 418-20.
160. Sasaki H, Nagura K, Ishino M, Tobioka H, Kotani K, Sasaki T. Cloning and characterization of cell adhesion kinase β, a novel protein-tyrosine kinase of the focal adhesion kinase subfamily. J Biol Chem 1995; 270: 21206-19.
161. Avraham S, London R, Fu Y et al. Identification and characterization of a novel related adhesion focal tyrosine kinase (RAFTK) from megakaryocytes and brain. J Biol Chem 1995; 270: 27742-51.
162. 1 muscarinic acetylcholine receptor. Proc Natl Acad Sci U S A 1998; 95: 5051-56.
163. Dikic I, Tokiwa G, Lev S, Courtneidge SA, Schlessinger J. A role for Pyk2 and Src in linking G-protein-coupled receptors with MAPK activation. Nature 1996; 383: 547-50.
164. Della Rocca CJ, van Biesen T, Daaka Y, Luttrell DK, Luttrell LM, Lefkowitz RJ. Ras-dependent mitogen-activated protein kinase activation by G protein-coupled receptors. Convergence of Gi-and Gq-mediated pathways on calcium/calmodulin, Pyk2, and Src kinase. J Biol Chem 1997; 272: 19125-32.
165. Luttrell LM, van Biesen T, Hawes BE et al. G protein-coupled receptors and their regulation. Activation of the MAPK signalling pathway by G protein coupled receptors. Adv Second Messenger Phosphoprotein Res 1997; 31: 263-77.
166. Chen YH, Pouyssegur J, Courtneidge SA, Van Obberghen Schilling E. Activation of Src family kinase activity by the G protein-coupled thrombin receptor in growth-responsive fibroblasts. J Biol Chem 1994; 269: 27372-77.
167. Tsai W, Morielli AD, Peralta EG. The m1 muscarinic receptor transactivates the EGF receptor to modulate ion channel activity. EMBO J 1997; 16: 4597-605.
168. Igishi T, Gutkind JS. Tyrosine kinases of the Src family participate in signaling to MAPK from both Gq and Gi-coupled receptors. Biochem Biophys Res Commun 1998; 244: 5-10.
169. 2-purinoceptor-mediated activation of the mitogen-activated protein kinase cascade in transfected CHO cells. Br J Pharmacol 1998; 124: 1491-99.
170. Eguchi S, Matsumoto T, Motley ED, Utsunomiya H, Inagami T. Identification of an essential signaling cascade for mitogen-activated protein kinase
171. 2+ signalling. Biochem J 1994; 299: 845-51.
172. Wolf MJ, Gross RW. The calcium-dependent association and functional coupling of calmodulin with myocardial phospholipase A2. Implications for cardiac cycle-dependent alterations to phospholipolysis. J Biol Chem 1996; 271: 20989-92.
173. Lee SB, Shin SH, Hepler JR, Gilman AG, Rhee SG. Activation of phospholipase C-beta 2 mutants by G protein alpha q and beta gamma subunits. J Biol Chem 1993; 268: 25952-57.
174. Park D, John DY, Lee CW, Lee KH, Rhee SG. Activation of phospholipase C isozymes by G protein beta gamma subunits. J Biol Chem 1993; 268: 4573-76.
175. Wu D, Katz A, Simon MI. Activation of phospholipase C beta2 by the alpha and beta gamma subunits of trimeric GTP-binding protein. Proc Natl Acad Sci U S A 1993; 90: 5297-301.
176. Boyer JL, Graber SG, Waldo GL, Harden TK, Garrison JC. Selective activation of phospholipase C by recombinant G-protein alpha-and beta gamma-subunits. J Biol Chem 1994; 269: 2814-19.
177. Boyer JL, Waldo GL, Harden TK. Beta gamma subunit activation of G-protein-regulated phospholipase C. J Biol Chem 1992; 267: 25451-56.
178. Dickenson JM, Hill SJ. Human 5-HTIB receptor stimulated inositol phospholipid hydrolysis in CHO cells: synergy with Gq-coupled receptors. Eur J Pharmacol 1998; 348: 279-85.
179. Parsons JT, Parsons SJ. Src family protein tyrosine kinases: cooperating with growth factor and adhesion signaling pathways. Curr Opin Cell Biol 1997; 9: 187-92.
180. van Biesen T, Luttrell LM, Hawes BE, Lefkowitz RJ. Mitogenic signaling via G protein-coupled receptors. Endocr Rev 1996; 17: 698-714.
181. Verkade P, Schrama LH, Verkleij AJ, Gispen WH, Oestreicher AB. Ultrastructural co-localization of calmodulin and B50/growth-associated protein-43 at the plasma membrane of proximal unmyelinated axon shafts studied in the model of the regenerating rat sciatic nerve. Neuroscience 1997; 79: 1207-18.
182. Deisseroth K, Heist EK, Tsien RW. Translocation of calmodulin to the nucleus supports CREB phosphorylation in hippocampal neurons. Nature 1998; 392: 198-202.
183. Nehmad R, Nadler H, Simantov R. Effects of acute and chronic morphine treatment of calmodulin activity of rat brain. Mol Pharmacol 1982; 22: 389-94.
184. Bonnet KA, Engelberg L, Gusik SA. Calmodulin increases in selective brain regions with opioid dependence. Life Sci 1982; 31: 2295-98.
185. Hoskins B, Ho IK. Effects of acute administration of and tolerance development to morphine on the striatal calmodulin systems in mice of different ages. Neuropeptides 1984; 5: 61-64.
186. Hoskins B, Ho IK, Meydrech EF. Effects of morphine and aging on brain calmodulin levels in mice. Exp Aging Res 1985; 11: 143-45.
187. Hordijk PL, Verlaan I, van Corven EJ, Moolenaar WH. Protein tyrosine phosphorylation induced by losophosphatidic acid in Rat-1 fibroblasts. Evidence that phosphorylation of MAPK is mediated by the Gi-p21ras pathway. J Biol Chem 1994; 269: 645-51.
188. van Biesen T, Hawes BE, Luttrell DK et al. Receptor-tyrosine-kinase-and Gβγ-mediated MAP kinase activation by a common signalling pathway. Nature 1995; 376: 781-84.
189. Yamauchi J, Nagao M, Kaziro Y, Itoh H. Activation of p38 mitogen-activated protein kinase by signaling through G protein-coupled receptors. Involvement of Gbetagamma and Galphaq/11-subunits. J Biol Chem 1997; 272: 27771-72.
190. Clapham DE, Neer EJ. G protein βγ subunits. Annu Rev Pharmacol Toxicol 1997; 37: 167-203.
191. Sugden PH, Clerk A. Regulation of the ERK subgroup of MAPK cascades through G protein-coupled receptors. Cell Signal 1997; 9: 337-51.
192. Yamaguchi M, Tanaka T, Waki M et al. Antisense src expression inhibits tyrosine phosphorylation of She and its association with Grb2 and Sos which leads to MAPK activation in U937 human leukemia cells. Leukemia 1997; 11: 497-503.
193. Lopez-Ilasaca M, Crespo P, Pellici PG, Gutkind JS, Wetzker R. Linkage of G protein-coupled receptors to the MAPK signalling pathway through PI 3-kinase γ. Science 1997; 275: 394-97.
194. Wan Y, Bence K, Hata A, Kurosaki T, Veillette A, Huang X-Y. Genetic evidence for a tyrosine kinase cascade preceding the mitogen-activated protein kinase cascade in vertebrate G protein signaling. J Biol Chem 1997; 272: 17209-15.
195. Alblas J, van Corven EJ, Hordijk PL, Milligan G, Moolenaar WH. Gi-mediated activation of the p21ras-mitogen-activated protein kinase pathway by alpha 2-adrenergic receptors expressed in fibroblasts. J Biol Chem 1993; 268: 22235-38.
196. Crespo P, Xu N, Daniotti JL, Troppmair J, Rapp UR, Gutkind JS. Signaling through transforming G protein-coupled receptors in NIH 3T3 cells involves c-Raf activation. Evidence for a protein kinase C-independent pathway. J Biol Chem 1994; 269: 21103-109.
197. Yawo H, Kuno M. How a nerve fiber repairs its cut end: involvement of phospholipase A. Science 1983; 222: 1351-53.
198. Nakamura S. Effects of manserin and fluoxetine on axonal regeneration of brain catecholamine neurons. NeuroReport 1991; 2: 525-28.
199. Nakamura S. Involvement of phospholipase A2 in axonal regeneration of brain noradrenergic neurones. NeuroReport 1993; 4: 371-74.
200. Nakamura S. Effects of phospholipase A2 inhibitors on the antidepressant-induced axonal regeneration of noradrenergic locus coeruleus neurons. Microsc Res Tech 1994; 29: 204-10.
201. Edström A, Briggman M, Ekström PA. Phospholipase A2 activity is required for regeneration of sensory axons in cultured adult sciatic nerves. J Neurosci Res 1996; 43: 183-89.
202. Smalheiser NR, Dissanayake S, Kapil A. Rapid regulation of neurite outgrowth and retraction by phospholipase A2-derived arachidonic acid and its metabolites. Brain Res 1996; 721: 39-48.
203. Ruegg UT, Cuenoud S, Fulpius BW, Simon EJ. Inactivation and solubilization of opiate receptors on phospholipases A2. Biochem Biophys Acta 1982; 685: 241-48.
204. Makimura M, Ito Y, Murakoshi Y. Inhibitory mechanisms of opioid binding receptor to phospholipase A2. Gen Pharmacol 1988; 19: 707-12.
205. Lazar DF, Medzhihradsky F. Differential inhibition of delta-opiate binding and low-Km GTPase stimulation by phospholipase A2 treatment. Prog Clin Biol Res 1990; 328: 113-16.
206. 3H]AMPA binding to rat cortical membranes. J Neurochem 1995; 65: 184-91.
207. Harrington MA, Shaw K, Zhong P, Ciaranelo RD. Agonist-induced desensitization and loss of high-affinity binding sites of stably expressed human 5-HT1A receptors. J Pharmacol Exp Ther 1994; 268: 1098-106.
208. Scriabine A. Calcium channel antagonists as neuroprotective agents. In: Bär PR, Flint Beal M eds. Neuroprotection in CNS diseases. New York: Marcel Dekker, 1997: 27-51.
209. Verity MA. Mechanisms of phospholipase A2 activation and neuronal injury. Ann N Y Acad Sci 1993; 679: 110-20.
210. Walton M, Sirimanne E, Williams C et al. Prostaglandin H synthase-2 and cytosolic phospholipase A2 in the hypoxi-ischemic brain: role in neuronal death or survival? Brain Res Mol Brain Res 1997; 50: 165-70.
211. Paul JA, Gregson NA. An immunohistochemical study of phospholipase A2 in peripheral nerve during Wallerian degeneration. J Neuroimmunol 1992; 39: 31-47.
212. Saal JS, Franson RC, Dobrow R, Saal JA, White AH, Goldthwaite N. High levels of inflammatory phospholipase A2 in lumbar disc herniations. Spine 1990: 15: 674-78.
213. Mitchell JA, Larkin S, Williams TJ. Cyclooxygenase-2: regulation and relevance in inflammation. Biochem Pharmacol 1995; 50: 1535-42.
214. 2+-triggered protease activity and cytoskeletal disassembly. J Neurosci 1991; 11: 3257-67.
215. Rehder V, Jensen RJ, Kater SB. The initial stages of neural regeneration are dependent upon intracellular calcium levels. Neuroscience 1992; 51: 565-74.
216. Ziv NE, Spira ME. Axotomy induces a transient and localized elevation of the free intracellular calcium concentration to the millimolar range. J Neurophysiol 1995; 74: 2625-37.
217. 2+-induced regulation of ion channel and MAPK functions. Nature 1995; 376: 737-44.
218. Vaughan CW, Ingram SL, Connor MA, Christie MJ. How opioids inhibit GABA-mediated neurotransmission. Nature 1997; 390: 611-14
219. Eddlestone GT. ATP-sensitive K channel modulation by products of PLA2 action in the insulin-secreting HIT cell line. Am J Physiol 1995; 268: C181-90.
220. Grigg JJ, Kozasa T, Nakajima Y, Nakajima S. Single-channel properties of a G-protein-coupled inward rectifier potassium channel in brain neurons. J Neurophysiol 1996; 75: 318-28.
221. Lin LL, Lin AY, Knopf JL. Cytosolic phospholipase A2 is coupled to hormonally regulated release of arachidonic acid. Proc Natl Acad Sci U S A 1992; 89: 6147-51.
222. Ghrib F, Pyronnet S, Bastic MJ, Fagot-Revurat P, Pradayrol L, Vaysse N. Arachidonic-acid-selective cytosolic phospholipase A2 is involved in gastrin-induced AR4-2J-cell proliferation. Int J Cancer 1998; 75: 239-45.
223. Akagi K, Nagao T, Urushidani T. Calcium oscillations in single cultured Chinese hamster ovary cells stably transfected with a cloned human cholecystokinin (CCK)B receptor. Jpn J Pharmacol 1997; 75: 33-42.
224. Yoshida H, Tsunoda Y, Owyang C. Cholecystokinin peptides stimulate pancreatic secretion by multiple signal transduction pathways. Am J Physiol 1997; 273: G735-47.
225. Simonsson E, Karlsson S, Ahren B. Involvement of phospholipase A2 and arachidonic acid in cholecystokinin-8-induced insulin secretion in rat islets. Regul Pept 1996; 65: 101-107.
226. Tsunoda Y, Owyang C. High-affinity CCK receptors are coupled to phospholipase A2 pathways to mediate pancreatic amylase secretion. Am J Physiol 1995; 269: G435-44.
227. Tsunoda Y, Owyang C. The regulatory site of functional GTP binding protein coupled to the high affinity cholecystokinin receptor and phospholipase A2 pathway is on the Gβ subunit of Gq protein in pancreatic acini. Biochem Biophys Res Commun 1985; 211: 648-55.
228. 2+ oscillations and pancreatic amylase secretion via mediation of G protein β/phospholipase A2/ arachidonic acid cascades. Biochem Biophys Res Commun 1994; 203: 1716-24.
229. 2+ oscillations in pancreatic acini. Biochem Biophys Res Commun 1993; 194: 1194-202.
230. Hidaka T, Nakano M, Shingu M, Sugiyama M, Inokuchi T, Ogura R. Stimulation of prostaglandin synthesis by cholecystokinin in primary culture cells of bovine gallbladder muscle. Prostaglandins Leukot Essent Fatty Acids 1989; 38: 113-17.
231. Schulz S, Höllt V. Opioid withdrawal activates MAPK in locus coeruleus neurones in morphine-dependent rats in vivo. Eur J Neurosci 1998; 10: 1196-201.
232. Lin L-L, Wartmann M, Lin AY, Knopf JL, Seith A, Davis RJ. cPLA2 is phosphorylated and activated by MAPK. Cell 1993; 72: 269-78.
233. Selbie LA, King NV, Dickenson JM, Hill SJ. Role of G-protein βγ subunits in the augmentation of P2Y2 (P2U) receptor-stimulated responses by neuropeptide Y Y1 Gi/o-coupled receptors. Biochem J 1997; 328: 153-58.
234. 1 receptors and endogenous cholecystokinin receptors in CHO cells. Eur J Pharmacol 1996; 302: 141-51.
235. 1 receptor-mediated modulation of thrombin-stimulated phospholipase C and phospholipase A2 activity in CHO cells. Eur J Pharmacol 1997; 321: 77-86.
236. 1 receptors and constitutive P2-purinoceptors in CHO-K1 cells. Br J Pharmacol 1995; 115: 1415-24.
237. 2. Biochim Biophys Acta 1982; 685: 241-48.
238. Zagon IS, McLaughlin PJ. Morphine and brain growth retardation in the rat. Pharmacology 1977; 15: 276-82.
239. Kitchen EA, Dawson W, Rainsford KD, Cawston T. Inflammation and possible modes of action of anti-inflammatory drugs. In: Rainsford KD ed. Anti-inflammatory and anti-rheumatic drugs. London: CRC Press, 1985: 21-87.
240. Denson DD, Worrell RT, Eaton DC. A possible role for phospholipase A2 in the action of general anesthetics. Am J Physiol 1996; 270: C636-44.
241. Jain MK, Jahagirdar DV. Action of phospholipase A2 on bilayers. Effects of inhibitors. Biochim Biophys Acta 1985; 814: 319-26.
242. Bovill JG. Mechanisms of actions of anaesthetic drugs. Curr Opin Anaesthesiol 1997; 10: 261-66.
243. Gupta C, Goldman AS. The arachidonic cascade is involved in the masculinizing action of testosterone on embryonic external genitalia in mice. Proc Natl Acad Sci U S A 1986; 83: 4346-49.
244. Ishigooka J, Tanaka K, Suzuki Y, Katori M, Miura S. Selective inhibitory effects of chlorpromazine and imipramine on platelet aggregation. Int Pharmacopsychiatry 1980; 15: 270-80.
245. Stockert M, Zieher LM, Medina JH. Interactions of phospholipids and free fatty acids with antidepressant recognition binding sites in rat brain. Adv Exp Med Biol 1992; 318: 325-30.
246. Stockert M, Medina JH. Modulation of cerebral cortical (3H) imipramine binding sites by phospholipase A2: possible role of unsaturated free fatty acids. Neurosci Res Commun 1990; 6: 89-94.
247. 32P] GTP labeling of multiple G protein α subunits. J Neurochem 1995; 64: 2534-43.
248. Prather PL, McGinn TM, Erickson LJ, Evans CJ, Loh HH, Law P-Y. Ability of δ-opioid receptors to interact with multiple G-proteins is independent of receptor density. J Biol Chem 1994; 269: 21293-302.
249. Prather PL, Loh HH, Law PY. Interactions of δ-opioid receptors with multiple G-proteins: a non-relationship between agonist potency to inhibit adenylyl cyclase and activation of G-proteins. Mol Pharmacol 1994; 45: 997-1003.
250. Prather PL, McGinn TM, Claude PA, Liu-Chen LY, Loh HH, Law PY. Properties of a κ-opioid receptor expressed in CHO cells: interaction with multiple G-proteins is not specific for any individual Ga subunit and is similar to that of other opioid receptors. Mol Brain Res 1995; 29: 336-46.
251. Laugwitz K, Offermanns S, Spicher K, Schulz G. μ-and δ opioid receptors differentially couple to G protein subtypes in membranes of human neuroblastoma cell lines. Neuron 1993; 10: 233-42.
252. Ueda H, Misawa H, Katada T, Ui M, Takagi H, Satoh M. Functional reconstitution of purified Gi and Go with μ-opioid receptors in guinea pig striatal membranes pretreated with micromolar concentrations of N-ethylmaleimide. J Neurochem 1990; 54: 841-48.
253. Traynor JR, Nahorski SR. Modulation by mu-opioid agonists of guanosine-5′-0-(3-(35S) thio) triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells. Mol Pharmacol 1995; 47: 848-54.
254. Tang TL, Kiang JG, Coté TE, Cox BM. Antisense oligodeoxynucleotide to the Gi2 protein α subunit sequence inhibits an opioid-induced increase in the intracellular free calcium concentration in ND8-37 neuroblastoma X dorsal root ganglion hybrid cells. Mol Pharmacol 1995; 45: 189-93.
255. Miyamae T, Fukushima N, Misu Y, Ueda H. δ opioid receptor mediates phospholipase C activation via Gi in xenopus oocytes. FEBS Lett 1993; 333: 311-14.
256. 3 cells. Mol Pharmacol 1995; 47: 1041-49.
257. Misawa H, Ueda H, Katada T, Ui M, Satoh M. A subtype of opioid kappa-receptor is coupled to inhibition of Gi1-mediated phospholipase C activity in the guinea pig cerebellum. FEBS Lett 1995; 361: 106-10.
258. Tsu RC, Chan JSC, Wong YH. Regulation of multiple effectors by the cloned δ opioid receptor: stimulation of phospholipase C and type II adenylyl cyclase. J Neurochem 1995; 64: 2700-707.
259. Lai HWL, Minami M, Satoh M, Wong YH. Gz coupling to the rat kappa opioid receptor. FEBS Lett 1995; 360: 97-99.
260. Budd K. The use of partial antagonist analgesics in the treatment of acute and chronic pain. Can Anaesth Soc J 1985; 32: 399-401.
261. Standifer KM, Rossi GC, Pasternak GW. Differential blockade of opioid analgesia by antisense oligodeoxynucleotides directed against various G protein a subunits. Mol Pharmacol 1996; 50: 293-98.
262. + channel-acting drugs. Br J Pharmacol 1995; 114: 1296-302.
263. Raffa RB, Martinez RP. The 'glibenclamide-shift' of centrally-acting nociceptive agents in mice. Brain Res 1995; 677: 277-82.
264. Del Pozo E, Ocaña M, El Mabrouki K, Baeyens JM. Potassium channels and analgesia. Dolor 1996; 11: 77-84.
265. Kamei J, Kawashima N, Narita M et al. Reduction in ATP-sensitive potassium channel-mediated antinociception in diabetic mice. Psychopharmacology 1994; 113: 318-21.
266. Belcheva MM, Barg J, McHale RJ et al. Differential down-and up-regulation of rat brain opioid receptor types and subtypes of buprenorphine. Mol Pharmacol 1993; 44: 173-79.
267. Chen J-C, Smith ER, Cahill M, Cohen R, Fischman JB. The opioid receptor binding of dezocine, morphine, fentanyl, butorphanol and nalbuphine. Life Sci 1993; 52: 389-96.
268. Clark MJ, Carter BD, Medzihradsky F. Selectivity of ligand binding to opioid receptors in brain membranes from the rat, monkey and guinea pig. Eur J Pharmacol 1988; 148: 343-51.
269. Richards ML, Sadée W. In vivo opiate receptor binding of oripavines to μ, δ and κ sites in rat brain as determined by an ex vivo labeling method. Eur J Pharmacol 1985; 114: 343-53.
270. Sadée W, Rosenbaum JS, Herz A. Buprenorphine: differential interaction with opiate receptor subtypes in vivo. J Pharmacol Exp Ther 1982; 223: 157-62.
271. 3H] fentanyl binding to the opiate receptor. Neuropharmacology 1983; 22: 447-52.
272. Villiger JW, Taylor KM. Buprenorphine: characteristics of binding sites in the rat central nervous system. Life Sci 1981; 29: 2699-708.
273. Childers SR, Creese I, Snowman AM, Synder SHI. Opiate receptor binding affected differentially by opiates and opioid peptides. Eur J Pharmacol 1979; 55: 11-18.
274. Ohta S, Niwa M, Nozaki M et al. The μ, δ and κ properties of various opioids. Masui 1995; 44: 1228-32.
275. Rothman RB, Ni Q, Xu H. Buprenorphine: a review of the binding literature. In: Cowan A, Lewis AJ eds. Buprenorphine: combatting drug abuse with a unique opioid. New York: Wiley-Liss, 1995: 19-29.
276. Connor MA, Keir MJ, Henderson G. δ-opioid receptor mobilization of intracellular calcium in SH-SY5Y cells: lack of evidence for δ-receptor subtypes. Neuropharmacology 1997; 36: 125-33.
277. Thomas AW, Kavaliers M, Prato S et al. Pulsed magnetic field induced 'analgesia' in the land snail, Capaea nemoralis, and the effects of μ, δ and κ opioid receptor agonists/antagonists. Peptides 1997; 18: 703-709.
278. Ruegg H, Yu WZ, Bodnar RJ. Opioid-receptor subtype agonist-induced enhancements of sucrose intake are dependent upon sucrose concentration. Physiol Behav 1997; 62: 121-28.
279. Olianas MC, Onali P. Participation of δ opioid receptor subtypes in the stimulation of adenylyl cyclase activity in rat olfactory bulb. J Pharmacol Exp Ther 1995; 275: 1560-67.
280. 2-, and μ-opioid receptor agonists on excitatory transmission in lamina II neurons of adult rat spinal cord. J Neurosci 1994; 14: 4965-71.
281. Maguire P, Tsai N, Kamal J et al. Pharmacological profiles of fentanyl analogs at μ, δ and κ opiate receptors. Eur J Pharmacol 1992; 213: 219-25.
282. McCormack KJ, Chapleo CB. Opioid receptors and myocardial protection. Do opioid agonists possess cardioprotective effects? Clin Drug Invest 1998; 15: 445-54.
283. Katade T, Ui M. Effect of in vivo pretreatment of rats with a new protein purified from Bordetella pertussis on an in vitro secretion of insulin: role of calcium. Endocrinology 1979; 104: 1822-27.
284. Bokoch GM, Katada T, Northup JK, Ui M, Gilman AG. Purification and properties of the inhibitory guanine nucleotide-binding regulatory component of adenylate cyclase. J Biol Chem 1984; 259: 3560-67.
285. Werling LL, McMahon PN, Cox BM. Selective changes in mu opioid receptor properties induced by chronic morphine exposure. Proc Natl Acad Sci U S A 1989; 86: 6393-97.
286. Wheeler-Aceto H, Cowan A. Buprenorphine and morphine cause antinociception by different transduction mechanisms. Eur J Pharmacol 1991; 195: 411-13.
287. Wheeler-Aceto H, Cowan A. Effect of pertussis toxin (PTX) on the antinociceptive profile of buprenorphine (B) and morphine (M): evidence for differential regulation of pain transmission. In: Harris L ed. Problems of drug dependence. Proceedings of the 53rd Annual Scientific Meeting of the Committee on Problems of Drug Dependence (Research monograph 119). Rockville, MD: NIDR, 1992: 309.
288. Parenti M, Tirone F, Giagnoni G, Pecora N, Parolaro D. Pertussis toxin inhibits the antinociceptive action of morphine in the rat. Eur J Pharmacol 1986; 124: 357-59.
289. Sanchez-Blazquez P, Garzon J. Pertussis toxin differentially reduces the efficacy of opioids to produce supraspinal analgesia in the mouse. Eur J Pharmacol 1988; 152: 357-61.
290. Hoehn K, Reid A, Sawynok J. Pertussis toxin inhibits antinociception produced by intrathecal injection of morphine, adrenaline and baclofen. Eur J Pharmacol 1988; 146: 65-72.
291. Wong CS, Su YF, Chang KJ, Watkins WD. Intrathecal pertussis toxin treatment attenuates opioid antinociception and reduces high-affinity state of opioid receptors. Anesthesiology 1992; 77: 691-99.
292. Womer DE, De Lapp NW, Shannon HE. Intrathecal pertussis toxin produces hyperalgesia and allodynia in mice. Pain 1997; 70: 223-28.
293. Wiesenfeld-Hallin Z. The effects of intrathecal morphine and naltrexone on autotomy in sciatic nerve sectioned rats. Pain 1984; 18: 267-78.
294. Bennett GJ, Xie YK. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 1988; 33: 87-107.
295. Kim SH, Chung JM. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 1992; 50: 355-63.
296. Shah S, Duttaroy A, Davis T, Yoburn BC. Spinal and supraspinal effects of pertussis toxin on opioid analgesia. Pharmacol Biochem Behav 1994; 49: 773-76.
297. Wong CS, Su YF, Watkins WD, Chang JK. Continuous intrathecal opioid treatment abolishes the regulatory effects of magnesium and guanine nucleotides on μ-opioid receptor binding in rat spinal membranes. J Pharmacol Exp Ther 1992; 262: 317-26.
298. Raffa RB, Martinez RP, Connelly CD. G-protein antisense oligodeoxynucleotides and μ-opioid supraspinal antinociception. Eur J Pharmacol 1994; 258: R5-R7.
299. McCormack K, Brune K, Budd K, Prather P. Experimental indices used to classify opioids as partial or full receptor agonists may have limited clinical utility [Abstract]. In: Jensen TS, Turner JA, Wiesenfeld-Hallin Z eds. Proceedings of the 8th World Congress on Pain (Progress in pain research and management, vol. 8). 1996 Aug 17-22; Vancouver, Canada. Seattle: IASP Press, 1997: Abst 88.
300. Luke MC, Hahn EF, Price M, Pasternak GE. Irreversible opiate agonists and antagonists: V. Hydrazone and acylhydrazone derivatives of naltrexone. Life Sci 1988; 43: 1249-56.
301. Price DD, Bennett GJ, Rafii A. Psychophysical observations on patients with neuropathic pain relieved by a sympathetic block. Pain 1989; 36: 273-88.
302. Cheng J, Roques BP, Gacel GA, Huang E, Pasternak GW. Kappa 3 opiate receptor binding in the mouse and rat. Eur J Pharmacol 1992; 226: 15-20.
303. Cheng J, Standifer KM, Tublin PR, Su W, Pasternak GW. Demonstration of kappa 3-opioid receptors in the SH-SY5Y human neuroblastoma cell line. J Neurochem 1995; 65: 170-75.
304. Berzetei-Gurske IP, White A, Polgar W, DeCosta BR, Pasternak GW, Toll L. The in vitro pharmacological characterization of naloxone benzoylhydrazone. Eur J Pharmacol 1995: 277: 257-63.
305. Paul D, Levison JA, Howard DH, Pick CG, Hahn EF, Pasternak GW. Naloxone benzoylhydrazone (NalBzoH) analgesia. J Pharmacol Exp Ther 1990; 255: 769-74.
306. Paul D, Pick CG, Tive LA, Pasternak GW. Pharmacological characterization of nalorphine, a kappa 3 analgesic. J Pharmacol Exp Ther 1991; 257: 1-7.
307. Pick CG, Peter Y, Schreiber S, Weizman R. Pharmacological characterization of buprenorphine, a mixed agonist-antagonist with kappa 3 analgesia. Brain Res 1997; 744: 41-46.
308. Avidor-Reiss T, Nevo I, Levy R, Pfeuffer T, Vogel Z. Chronic opioid treatment induces adenylyl cyclase V superactivation: involvement of Gβγ. J Biol Chem 1996; 271: 21309-15.
309. Thomas JM, Hoffman BB. Buprenorphine prevents and reverses the expression of chronic etorphine-induced sensitization of adenylyl cyclase in SK-N-SH human neuroblastoma cells. J Pharmacol Exp Ther 1993; 264: 368-74.
310. Van Gelderen JG, Daeffler L, Scherrer D, Mousli M, Landry Y, Giles JP. M2-muscarinic receptors: how does ligand binding affinity relate to intrinsic activity? J Recept Signal Transduct Res 1996; 16: 135-48.
311. McCormack K, Prather P, Chapleo C. Some new insights into the effects of opioids in phasic and tonic nociceptive tests. Pain 1998; 78: 79-98.
312. Chapleo CB. Controlling pain in the 21st century. Drug News Perspect 1997; 10: 443-47.
313. McLaughlin CR, Dewey RL. A comparison of the antinociceptive effects of opioid agonists in neonatal and adult rats in phasic and tonic nociceptive tests. Pharmacol Biochem Behav 1994; 49: 1017-23.
314. Wang J-J, Ho S-T, Hu O-Y, Chu K-M. An innovative cold tail-flick test: the cold ethanol tail-flick test. Anesth Analg 1995; 80: 102-107.
315. Jasmin L, Kohan L, Franssen M, Janni G, Goff JR. The cold plate as a test of nociceptive behaviors: description and application to the study of chronic neuropathic and inflammatory pain models. Pain 1998; 75: 367-82.
316. Menendez L, Bester H, Besson JM, Bernard JF. Parabrachial area: electrophysiological evidence for an involvement in cold nociception. J Neurophysiol 1996; 75: 2099-116.
317. Le Bars D, Chitour D, Kraus E, Clot AM, Dickenson AH, Besson JM. The effect of systemic morphine upon diffuse noxious inhibitory controls (DNIC) in the rat: evidence for a lifting of certain descending inhibitory controls of dorsal horn convergent neurones. Brain Res 1981; 215: 257-74.
318. Bouhassira D, Bing Z, Le Bars D. Studies of brain structures involved in diffuse noxious inhibitory controls in the rat: the rostral ventromedial medulla. J Physiol (Lond) 1993; 463: 667-87.
319. Guirimand F, Chauvin M, Willer JC, Le Bars D. Buprenorphine blocks diffuse noxious inhibitory controls in the rat. Eur J Pharmacol 1995; 294: 651-59.
320. Niv D, Nemirovsky A, Metzner J, Rudick V, Jurna I, Urca G. Antinociceptive effect induced by the combined administration of spinal morphine and systemic buprenorphine. Anesth Analg 1998; 87: 583-86.
321. Casey PJ, Fong HKW, Simon MI, Gilman AG. Gz, a guanine nucleotide-binding protein with unique biochemical properties. J Biol Chem 1990; 265: 2383-90.
322. Fields TA, Casey PJ. Phosphorylation of Gzα by protein kinase C blocks interaction with the beta gamma complex. J Biol Chem 1995; 270: 23119-25.
323. Kozasa T, Gilman AG. Protein kinase C phosphorylates G(12α) and inhibits its interaction with Gβγ. J Biol Chem 1996; 271: 12562-67.
324. Prather P, Brune K, Budd K, McCormack K. How far does functional promiscuity amongst receptor subtypes and G proteins explain diversity in clinical effects and interactions [Abstract]? In: Jensen TS, Turner JA, Wiesenfeld-Hallin Z eds. Proceedings of the 8th World Congress on Pain (Progress in pain research and management, vol. 8). 1996 Aug 17-22; Vancouver, Canada. Seattle: IASP Press, 1997: 460.
325. Fields TA, Casey PJ. Signalling functions and biochemical properties of pertussis toxin-resistant G proteins. Biochem J 1997; 321: 561-71.
326. Hinton DR, Blanks JC, Fong HKW, Casey PJ, Hildebrandt E, Simons MI. Novel localization of a G protein, Gza, in neurons of brain and retina. J Neurosci 1990; 10: 2763-70.